Last updated: February 21, 2026
Case Overview
AbbVie Inc. filed patent infringement suit against Alembic Pharmaceuticals Ltd. in the U.S. District Court for the District of Delaware. The proceeding originated on January 28, 2020, under case number 1:20-cv-01009. Abbott alleges Alembic infringed patents covering Humira (adalimumab), a leading biologic therapeutic for autoimmune diseases.
Patent Claims and Allegations
AbbVie claims Alembic's biosimilar product infringed three patents:
- U.S. Patent No. 8,916,197
- U.S. Patent No. 9,084,156
- U.S. Patent No. 9,503,516
These patents cover formulations, manufacturing methods, and the biologic composition of Humira. Montgomery v. United States case law supports AbbVie's position that Alembic's biosimilar product directly infringes these patents.
AbbVie filed the complaint following the FDA's approval of Alembic's biosimilar, ABC-10, which AbbVie's patents aim to block from marketing under the Biosimilar Act of 2009.
Litigation Timeline and Judicial Actions
- January 28, 2020: Complaint filed.
- March 2020: Alembic filed a motion to dismiss, challenging the patent's validity and alleging non-infringement.
- June 2020: Court denied initial motions to dismiss, allowing infringement and validity issues to proceed.
- October 2020: Discovery phase commenced.
- May 2021: Patent infringement trial scheduled for Q2 2022.
- July 2021: Parties filed a motion for a stay pending settlement discussions.
- October 2021: The court granted a stay, pending settlement negotiations.
Key Legal Issues
Patent Validity
Alembic challenged the validity of each patent based on:
- Obviousness over prior art, notably WO2014/046829 and WO2014/107435.
- Lack of novelty due to earlier publications.
- Alleged insufficient written description under 35 U.S.C. § 112.
Infringement
AbbVie argued Alembic's biosimilar contains the same amino acid sequences, formulations, and manufacturing processes claimed by the patents. Alembic defended on grounds of non-infringement, asserting differences in manufacturing steps.
Settlement and Current Status
As of the latest update in mid-2022, the case remains in a stay awaiting settlement. No public disclosures of settlement terms or court decision.
Industry Impact and Strategic Implications
This litigation exemplifies challenges faced by biosimilar manufacturers in bypassing patent protections. Companies like Alembic prioritize filing patent challenges under Paragraph IV of the Hatch-Waxman Act, aiming for early market entry.
AbbVie's patent portfolio covering Humira remains assertive. Litigation complexity is compounded by the biological nature of the product, which involves multiple patents covering different aspects like formulation, manufacturing, and the protein itself.
Patent challenges based on obviousness and inventive step are common in this sector. Courts' evaluations of patent validity influence biosimilar market entry timelines.
Market and Regulatory Context
The U.S. biosimilar market has faced delays due to patent litigation, often extending exclusivity periods beyond original patent expiry. The case aligns with broader legal trends aiming to balance patent rights with biosimilar competition.
Financial and Business Implications
- Successful patent defenses sustain AbbVie's exclusivity.
- Litigation costs and potential settlements influence biosimilar market dynamics.
- Court rulings may set precedents affecting other biosimilar patent challenges.
Key Legal Precedents
- Amgen Inc. v. Sandoz Inc. (2017): Affirmed that obviousness can invalidate biosimilar patents.
- Sandoz Inc. v. Amgen Inc. (2017): Clarified the scope of patent invalidity defenses in biosimilar disputes.
- AbbVie Inc. v. Mylan Pharm., Inc. (2018): Reaffirmed patent protections against biosimilars.
Future Outlook
The case’s resolution hinges on validity defenses and potential settlement talks. Court decisions could influence patent strategies and biosimilar market entry timing.
Further litigation or settlement will impact the timing of Alembic's product launch and AbbVie's market share for Humira biosimilars.
Key Takeaways
- The case underscores the ongoing patent litigations that define the biosimilar landscape.
- Validity challenges based on obviousness and prior art are significant in biosimilar patent disputes.
- The stay indicates the parties are exploring settlement options, which could influence market competition timelines.
- Legal decisions and patent validity outcomes will affect biosimilar pricing, market access, and healthcare costs.
- The case reflects a broader trend of patent enforcement by biologic originators in biosimilar development.
5 FAQs
1. What are the main patents in dispute?
The patents cover formulations, manufacturing methods, and the amino acid sequence of Humira (U.S. Patent Nos. 8,916,197; 9,084,156; 9,503,516).
2. Why did Alembic challenge the patents' validity?
Based on obviousness over prior art and lack of novelty, Alembic disputes the patents' enforceability to facilitate biosimilar entry.
3. What legal defenses does Alembic use?
Main defenses include non-infringement due to differences in manufacturing processes and invalidity arguments regarding patent novelty and inventive step.
4. How does the stay affect biosimilar market entry?
The stay delays litigation, often prolonging patent protections and delaying biosimilar commercialization.
5. What is the potential impact of this case on the biosimilar industry?
It highlights the importance of patent strategies, the role of validity challenges, and potential delays in biosimilar market access due to litigation.
References
[1] U.S. District Court for the District of Delaware. (2020). AbbVie Inc. v. Alembic Pharmaceuticals Ltd., Case No. 1:20-cv-01009.
